Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

TESARO INC (TSRO)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2017 07/24/2017 07/25/2017 07/26/2017 07/27/2017 Date
131.97(c) 129.87(c) 128.95(c) 130.06(c) 126.7 Last
1 697 801 912 113 634 227 356 020 991 161 Volume
+2.29% -1.59% -0.71% +0.86% -2.58% Change
More quotes
Financials ($)
Sales 2017 115 M
EBIT 2017 -472 M
Net income 2017 -479 M
Finance 2017 417 M
Yield 2017 -
Sales 2018 414 M
EBIT 2018 -260 M
Net income 2018 -265 M
Finance 2018 268 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 57,2x
EV / Sales2018 16,3x
Capitalization 7 006 M
More Financials
Company
TESARO, Inc. engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and consists of the following portfolio: Rolapitant IV and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010... 
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
01:16p TESARO,INC. (NASDAQ : TSRO) Files An 8-K Entry into a Material Definitive Agreem..
01:12p TESARO, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclos..
01:01p TESARO : and Takeda Enter Into Exclusive Licensing Agreement to Develop and Comm..
01:00p TAKEDA PHARMACEUTICAL : TESARO and Takeda Enter Into Exclusive Licensing Agreeme..
07/26 TESARO : STA to supply intermediate for Tesaro `s $117k-a-year cancer drug Zejul..
07/25 TESARO : to Announce Second-Quarter 2017 Financial Results on August 8, 2017
07/25 TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017
07/25 TESARO : STA Signs Supply Agreement with TESARO
07/14 BIOTECH MOVERS : TESARO Inc (NASDAQ:TSRO) and Mylan N.V. (NASDAQ:MYL)
07/06 Stocks Under Scanner in the Biotech Space — Achillion Pharma, Kite Phar..
More news
Sector news : Bio Therapeutic Drugs
08:13pDJUNITED THERAPEUTICS : in Settlement Talks With Justice Department -- Update
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJCELGENE : Settles Lawsuit Over Improper Promotion of Cancer Drugs
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
More sector news : Bio Therapeutic Drugs
Latest Tweets
05:23pTESARO out-licenses niraparib to Takeda for up to $340M  
04:53pTesaro partners with Takeda in Asia, bagging a $340M deal for Zejula: Endpoin.. 
03:12p$TSRO: Tesaro and Takeda (TKPYY) announce an exclusive licensing agreement fo.. 
02:19p$TSRO (-0.8% pre) Tesaro partners with Takeda in Asia, bagging a $340M deal f..
1
01:50pTESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Com.. 
More tweets
Qtime:23
News from SeekingAlpha
11:23a TESARO out-licenses niraparib to Takeda for up to $340M
07/25 BIOTECH BONANZA : The Next Leg Up
07/21 Tesaro's Stock Dip Is Nothing To Be Afraid Of
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/13 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 177 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson Chief Financial Officer & Executive Vice President
Martin H. Huber Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC-3.29%7 006
AMGEN20.30%129 349
CELGENE CORPORATION19.01%107 559
GILEAD SCIENCES3.60%96 946
REGENERON PHARMACEUTICALS39.87%54 807
VERTEX PHARMACEUTICALS121.83%40 703